You just read:

Azevan Pharmaceuticals Reports Positive Phase 2 Exploratory Clinical Study Results with SRX246 in Intermittent Explosive Disorder

News provided by

Azevan Pharmaceuticals, Inc.

14 Sep, 2016, 10:39 ET